SCD and prostate carcinoma: Pharmacologic inhibition of SCD1 has demonstrated a decrease in the MUFA/SFA ratio and cell proliferation in lung cancer cells [43], and has blocked signaling processes involved in oncogenesis and cancer progression in prostate cancer cells [44].